Bank of America’s enVVeno Medical NVNO Stock Holding History

Bank of America’s Portfolio NVNO Stock Details NVNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,940	Closed	-$61.5K	–	8067
2025 Q3	$61.5K	Buy	+1,940	New	+$198K	﹤0.01%	6781

Other funds holding NVNO

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

WIM

Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America's NVNO Position: Q1 2026 in Review

Bank of America sold out of enVVeno Medical (NVNO) in Q1 2026, closing a stake of 58 shares — an estimated $648 sold.

Bank of America first reported a position in NVNO in Q3 2019 and held it in 12 quarters. The position peaked at $97K in Q3 2021. 17 funds tracked by Wall St. Rank hold NVNO as of Q1 2026.

Bank of America reported no remaining enVVeno Medical position as of Q1 2026 after selling out during the quarter.
Bank of America sold 58 enVVeno Medical shares in Q1 2026, an estimated $648.
Bank of America first reported a position in enVVeno Medical in Q3 2019 and held it in 12 quarters.
Bank of America's enVVeno Medical position peaked at $97K in Q3 2021.
17 funds tracked by Wall St. Rank held enVVeno Medical as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.